M33 Growth I L.P.'s Form 4 filing
Starling Oncology, Inc. (DFPH) · filed May 22, 2025
- Accession no.
- 0001213900-25-046977
- Filed
- May 22, 2025, 7:38 PM ET
- Trade date
- May 20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $5.43M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| M33 Growth I L.P.CIK 0001718621 | Director, 10% Owner |
| Toi M, LLCCIK 0001892968 | Director, 10% Owner |
| M33 Growth I GP LLCCIK 0001894303 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2025 | Common Stock | SSaleDisposed | −1,796,468 | $2.71 | −$4,873,638.04 | 14,624,233 | Direct | |
| May 20, 2025 | Common Stock | SSaleDisposed | −203,532 | $2.71 | −$552,161.96 | 1,349,048 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.